P
8.56
-0.21 (-2.39%)
| Previous Close | 8.77 |
| Open | 8.78 |
| Volume | 776,626 |
| Avg. Volume (3M) | 1,350,945 |
| Market Cap | 760,165,312 |
| Price / Sales | 10.65 |
| Price / Book | 4.52 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Profit Margin | -98.10% |
| Operating Margin (TTM) | -85.88% |
| Diluted EPS (TTM) | -1.29 |
| Quarterly Revenue Growth (YOY) | 5.50% |
| Total Debt/Equity (MRQ) | 21.81% |
| Current Ratio (MRQ) | 6.91 |
| Operating Cash Flow (TTM) | -42.70 M |
| Levered Free Cash Flow (TTM) | -23.09 M |
| Return on Assets (TTM) | -17.90% |
| Return on Equity (TTM) | -51.25% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Diagnostics & Research (US) | Bullish | Mixed |
| Diagnostics & Research (Global) | Bullish | Mixed | |
| Stock | Personalis, Inc. | Bullish | Bullish |
AIStockmoo Score
-0.3
| Analyst Consensus | 4.0 |
| Insider Activity | NA |
| Price Volatility | -4.5 |
| Technical Moving Averages | 0.0 |
| Technical Oscillators | -0.5 |
| Average | -0.25 |
|
Personalis Inc is a provider of genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and other next-generation cancer immunotherapies. It has one segment, the sale of sequencing and data analysis services. Its products include ImmunoID NeXT, NeXT Personal, NeXT Dx Test, and other pharma research solutions. |
|
| Sector | Healthcare |
| Industry | Diagnostics & Research |
| Investment Style | Small Value |
| % Held by Insiders | 31.49% |
| % Held by Institutions | 46.11% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 13.00 (HC Wainwright & Co., 51.87%) | Buy |
| Median | 12.00 (40.19%) | |
| Low | 10.00 (Needham, 16.82%) | Buy |
| Average | 11.60 (35.51%) | |
| Total | 4 Buy, 1 Hold | |
| Avg. Price @ Call | 8.62 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Morgan Stanley | 02 Dec 2025 | 11.00 (28.50%) | Hold | 10.10 |
| 11 Nov 2025 | 9.00 (5.14%) | Hold | 8.44 | |
| BTIG | 11 Nov 2025 | 12.00 (40.19%) | Buy | 8.44 |
| 22 Oct 2025 | 11.00 (28.50%) | Buy | 8.93 | |
| Guggenheim | 11 Nov 2025 | 12.00 (40.19%) | Buy | 8.44 |
| HC Wainwright & Co. | 11 Nov 2025 | 13.00 (51.87%) | Buy | 8.44 |
| 06 Nov 2025 | 10.00 (16.82%) | Buy | 7.19 | |
| Needham | 05 Nov 2025 | 10.00 (16.82%) | Buy | 7.66 |
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 17 Dec 2025 | Announcement | Personalis Announces New Publication Applying Ultrasensitive ctDNA Testing to Monitoring Cancer Immunotherapy Response Across Solid Tumors |
| 11 Dec 2025 | Announcement | New Publication Demonstrates the Importance of NeXT Personal Ultrasensitive Detection of Residual Disease in Lung Cancer |
| 18 Nov 2025 | Announcement | Personalis to Participate in the Piper Sandler 37th Annual Healthcare Conference |
| 10 Nov 2025 | Announcement | Personalis Announces Medicare Coverage for Ultrasensitive MRD Test in Breast Cancer |
| 04 Nov 2025 | Announcement | Personalis Reports Third Quarter 2025 Financial Results |
| 21 Oct 2025 | Announcement | Personalis to Announce Third Quarter 2025 Financial Results |
| 16 Oct 2025 | Announcement | Personalis Announces New Data from a Landmark Lung Cancer Trial Utilizing Ultrasensitive MRD Testing |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |